Association of CYP2C19, TNF-α, NOD1, NOD2, and PPARγ polymorphisms with peptic ulcer disease enhanced by Helicobacter pylori infection

References

1. ↵
   1. Stolte M,
   2. Meining A

   (2001) The updated Sydney system:Classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 15:591–598.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
2. ↵
   1. Graham DY

   (2015) Helicobacter pylori update:Gastric cancer reliable therapy and possible benefits. Gastroenterology 148:719–731.

   OpenUrlCrossRefPubMedGoogle Scholar
3. ↵
   1. Khan AR

   (1999) Comparison of H. pylori-gastritis among young and old patients by using“the modified Sydney system of classification and grading” Saudi J Gastroenterol 5:81–84.

   OpenUrlGoogle Scholar
4. ↵
   1. Mitchell H,
   2. Katelaris P

   (2016) Epidemiology clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust 204:367–380.

   OpenUrlGoogle Scholar
5. ↵
   1. Goudarzi H,
   2. Seyedjavadi SS,
   3. Fazeli M,
   4. Azad M,
   5. Goudarzi M

   (2015) Genotyping of peroxisome proliferator-activated receptor gamma in iranian patients with Helicobacter pylori infection. Asian Pacific J Cancer Prev 16:5219–5223.

   OpenUrlGoogle Scholar
6. ↵
   1. Ram MR,
   2. Goh KL,
   3. Leow AH,
   4. Poh BH,
   5. Loke MF,
   6. Harrison R,
   7. et al.

   (2015) Polymorphisms at locus 4p14 of Toll-like receptors TLR-1 and TLR-10 confer susceptibility to gastric carcinoma in Helicobacter pylori infection. PLoS One 10:1–15.

   OpenUrlCrossRefPubMedGoogle Scholar
7. ↵
   1. Wang P,
   2. Zhang L,
   3. Jiang JM,
   4. Ma D,
   5. Tao HX,
   6. Yuan SL,
   7. et al.

   (2012) Association of NOD1 and NOD2 genes polymorphisms with Helicobacter pylori related gastric cancer in a Chinese population. World J Gastroenterol 18:2112–2120.

   OpenUrlPubMedGoogle Scholar
8. ↵
   1. Drici AE,
   2. Moulessehoul S,
   3. Tifrit A,
   4. Diaf M,
   5. Turki DK,
   6. Bachir M,
   7. et al.

   (2016) Effect of IL-1? and IL-1RN polymorphisms in carcinogenesis of the gastric mucosa in patients infected with Helicobacter pylori in Algeria. Libyan J Med 11:1–7.

   OpenUrlCrossRefGoogle Scholar
9. ↵
   1. Santos JC,
   2. Ladeira MS,
   3. Pedrazzoli J,
   4. Ribeiro ML

   (2012) Relationship of IL-1 and TNF-? polymorphisms with Helicobacter pylori in gastric diseases in a Brazilian population. Brazilian J Med Biol Res 45:811–817.

   OpenUrlPubMedGoogle Scholar
10. ↵
    1. Han R,
    2. Lu H,
    3. Jiang MW,
    4. Tan KW,
    5. Peng Z,
    6. Hu JL,
    7. et al.

    (2016) Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. Gastroenterol Res Pract 2016:1–6.

    OpenUrlPubMedGoogle Scholar
11. ↵
    1. Kuo CH,
    2. Lu CY,
    3. Shih HY,
    4. Liu CJ,
    5. Wu MC,
    6. Hu HM,
    7. et al.

    (2014) CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol 20:16029–16036.

    OpenUrlPubMedGoogle Scholar
12. ↵
    1. Hunfeld NG,
    2. Touw DJ,
    3. Mathot RA,
    4. Van Schaik RH,
    5. Kuipers EJ

    (2012) A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 35:810–818.

    OpenUrlCrossRefPubMedGoogle Scholar
13. ↵
    1. Jainan W,
    2. Vilaichone RK

    (2014) Effects of the CYP2C19 genetic polymorphism on gastritis peptic ulcer disease peptic ulcer bleeding and gastric cancer. Asian Pacific J Cancer Prev 15:10957–10960.

    OpenUrlGoogle Scholar
14. ↵
    1. Saxena A,
    2. Shukla SK,
    3. Prasad KN,
    4. Ghoshal UC

    (2012) Analysis of p53. K-ras gene mutation &Helicobacter pylori infection in patients with gastric cancer &peptic ulcer disease at a tertiary care hospital in north India. Indian J Med Res 136:664–670.

    OpenUrlPubMedGoogle Scholar
15. 1. Belda S,
    2. Saez J,
    3. Santibáñez M,
    4. Rodríguez JC,
    5. Sola-Vera J,
    6. Ruiz-García M,
    7. et al.

    (2012) Relationship between bacterial load, morbidity and cagA gene in patients infected by Helicobacter pylori. Clin Microbiol Infect 18:E251–E253.

    OpenUrlCrossRefPubMedGoogle Scholar
16. ↵
    1. Biernat MM,
    2. Gosciniak G,
    3. Iwanczak B

    (2014) Prevalence of Helicobacter pylori cagA vacA, iceA babA2 genotypes in Polish children and adolescents with gastroduodenal disease. Advances in Hygiene &Experimental Medicine/PostepyHigienyiMedycynyDoswiadczalnej 68:1015–1021.

    OpenUrlGoogle Scholar
17. ↵
    1. Suzuki H,
    2. Mori H

    (2018) World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol 53:354–361.

    OpenUrlCrossRefGoogle Scholar
18. ↵
    1. Bridge DR,
    2. Merrell DS

    (2013) Polymorphism in the Helicobacter pylori CagA and VacA toxins and disease. Gut microbes 4:101–117.

    OpenUrlCrossRefGoogle Scholar
19. ↵
    1. Fashner J,
    2. Gitu AC

    (2015) Diagnosis and treatment of peptic ulcer disease and H. pylori infection. Am Fam Physician 91:236–242.

    OpenUrlPubMedGoogle Scholar
20. ↵
    1. Dunne C,
    2. Dolan B,
    3. Clyne M

    (2014) Factors that mediate colonization of the human stomach by Helicobacter pylori. World J Gastroenterol 20:5610–5624.

    OpenUrlCrossRefPubMedGoogle Scholar
21. ↵
    1. Sychev DA,
    2. Denisenko NP,
    3. Sizova ZM,
    4. Grachev AV,
    5. Velikolug KA

    (2015) The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 8:111–114.

    OpenUrlGoogle Scholar
22. ↵
    1. Lin YA,
    2. Wang H,
    3. Gu ZJ,
    4. Wang WJ,
    5. Zeng XY,
    6. Du YL,
    7. et al.

    (2017) Effect of CYP2C19 gene polymorphisms on proton pump inhibitor, amoxicillin, and levofloxacin triple therapy for eradication of Helicobacter Pylori. Med Sci Monit 23:2701–2707.

    OpenUrlGoogle Scholar
23. ↵
    1. Kuo CH,
    2. Liu CJ,
    3. Yang CC,
    4. Kuo FC,
    5. Hu HM,
    6. Shih HY,
    7. et al.

    (2016) A rapid and accurate method to evaluate Helicobacter pylori infection, clarithromycin resistance, and CYP2C19 genotypes simultaneously from gastric juice. Med (United States) 95:1–7.

    OpenUrlGoogle Scholar
24. ↵
    1. Velin D,
    2. Straubinger K,
    3. Gerhard M

    (2016) Inflammation immunity, and vaccines for Helicobacter pylori infection. Helicobacter 21:26–29.

    OpenUrlCrossRefGoogle Scholar
25. ↵
    1. Sonnenberg A,
    2. Turner KO,
    3. Spechler SJ,
    4. Genta RM

    (2017) The influence of Helicobacter pylori on the ethnic distribution of Barrett's metaplasia. Aliment Pharmacol Ther 45:283–290.

    OpenUrlGoogle Scholar
26. ↵
    1. Varga MG,
    2. Piazuelo MB,
    3. Romero-Gallo J,
    4. Delgado AG,
    5. Suarez G,
    6. Whitaker ME,
    7. et al.

    (2016) TLR9 activation suppresses inflammation in response to Helicobacter pylori infection. Am J Physiol - Gastrointest Liver Physiol 311:G852–G858.

    OpenUrlCrossRefPubMedGoogle Scholar
27. ↵
    1. Li X,
    2. Liu S,
    3. Luo J,
    4. Liu A,
    5. Tang S,
    6. Liu S,
    7. et al.

    (2015) Helicobacter pylori induces IL-1? and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling pathway. Pathog Dis 73:1–8.

    OpenUrlCrossRefPubMedGoogle Scholar
28. ↵
    1. Kameoka S,
    2. Kameyama T,
    3. Hayashi T,
    4. Sato S,
    5. Ohnishi N,
    6. Hayashi T,
    7. et al.

    (2016) Helicobacter pylori induces IL-1? protein through the inflammasome activation in differentiated macrophagic cells. Biomed Res 37:21–27.

    OpenUrlCrossRefGoogle Scholar
29. ↵
    1. Murphy G,
    2. Thornton J,
    3. McManus R,
    4. Swan N,
    5. Ryan B,
    6. Hughes DJ,
    7. O'Morain CA,
    8. et al.

    (2009) Association of gastric disease with polymorphisms in the inflammatory related genes IL-1B, IL-1RN, IL-10, TNF and TLR4. Eur J Gastroenterol Hepatol 21:630–635.

    OpenUrlPubMedGoogle Scholar
30. ↵
    1. Chen G,
    2. Tang N,
    3. Wang C,
    4. Xiao L,
    5. Yu M,
    6. Zhao L,
    7. et al.

    (2017) TNF-?-inducing protein of Helicobacter pylori induces epithelial-mesenchymal transition (EMT) in gastric cancer cells through activation of IL-6/STAT3 signaling pathway. Biochem Biophys Res Commun 484:311–317.

    OpenUrlGoogle Scholar
31. ↵
    1. Siregar GA,
    2. Halim S,
    3. Sitepu RR

    (2015) Serum TNF-a IL-8, VEGF levels in Helicobacter pylori infection and their association with degree of gastritis. Acta Med Indones 47:120–126.

    OpenUrlGoogle Scholar
32. ↵
    1. You W,
    2. Lai X,
    3. Lv J,
    4. Chen P,
    5. Xia J,
    6. Cui F,
    7. et al.

    (2016) Association of tumor necrosis factor-? gene polymorphisms with susceptibility to Helicobacter pylori-associated gastroduodenal diseases in the Chinese population. Int J Clin Exp Pathol 9:12836–12842.

    OpenUrlGoogle Scholar
33. ↵
    1. Li ZX,
    2. Wang YM,
    3. Tang FB,
    4. Zhang L,
    5. Zhang Y,
    6. Ma JL,
    7. et al.

    (2015) NOD1 and NOD2 genetic variants in association with risk of gastric cancer and its precursors in a Chinese population. PLoS One 10:1–14.

    OpenUrlCrossRefPubMedGoogle Scholar
34. ↵
    1. Tran LS,
    2. Tran D,
    3. De Paoli A,
    4. D'Costa K,
    5. Creed SJ,
    6. Ng GZ,
    7. et al.

    (2018) NOD1 is required for Helicobacter pylori induction of IL-33 responses in gastric epithelial cells. Cell Microbiol 20:1–12.

    OpenUrlGoogle Scholar